Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDSI NASDAQ:FLXN NASDAQ:OGI NASDAQ:PGNX NASDAQ:STSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSIBioDelivery Sciences International$5.59$5.58$2.50▼$5.62$577.05M0.563.34 million shs2.09 million shsFLXNFlexion Therapeutics$25.550.0%$9.20$4.30▼$13.66$1.29B1.531.18 million shs1,149 shsOGIOrganigram Global$1.71+3.0%$1.53$0.85▼$2.00$222.52M1.49709,171 shs666,707 shsPGNXProgenics Pharmaceuticals$4.10$4.10$1.89▼$6.37$355.05M1.891.16 million shs34.93 million shsSTSASatsuma Pharmaceuticals$1.10$1.08$0.59▼$8.08$36.47M0.1701,788 shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSIBioDelivery Sciences International0.00%0.00%0.00%0.00%0.00%FLXNFlexion Therapeutics0.00%+0.35%+0.97%+180.15%+180.15%OGIOrganigram Global0.00%+0.61%+16.08%+16.08%-10.75%PGNXProgenics Pharmaceuticals0.00%0.00%0.00%0.00%0.00%STSASatsuma Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSIBioDelivery Sciences International$5.59$5.58$2.50▼$5.62$577.05M0.563.34 million shs2.09 million shsFLXNFlexion Therapeutics$25.550.0%$9.20$4.30▼$13.66$1.29B1.531.18 million shs1,149 shsOGIOrganigram Global$1.71+3.0%$1.53$0.85▼$2.00$222.52M1.49709,171 shs666,707 shsPGNXProgenics Pharmaceuticals$4.10$4.10$1.89▼$6.37$355.05M1.891.16 million shs34.93 million shsSTSASatsuma Pharmaceuticals$1.10$1.08$0.59▼$8.08$36.47M0.1701,788 shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSIBioDelivery Sciences International0.00%0.00%0.00%0.00%0.00%FLXNFlexion Therapeutics0.00%+0.35%+0.97%+180.15%+180.15%OGIOrganigram Global0.00%+0.61%+16.08%+16.08%-10.75%PGNXProgenics Pharmaceuticals0.00%0.00%0.00%0.00%0.00%STSASatsuma Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDSIBioDelivery Sciences International 0.00N/AN/AN/AFLXNFlexion Therapeutics 0.00N/AN/AN/AOGIOrganigram Global 0.00N/AN/AN/APGNXProgenics Pharmaceuticals 0.00N/AN/AN/ASTSASatsuma Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDSIBioDelivery Sciences International$166.70M3.46$0.36 per share15.42$1.90 per share2.94FLXNFlexion Therapeutics$85.55M15.03N/AN/A($0.34) per share-75.15OGIOrganigram Global$117.47M1.95N/AN/A$2.07 per share0.83PGNXProgenics Pharmaceuticals$34.99M10.15N/AN/A$0.54 per share7.59STSASatsuma PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDSIBioDelivery Sciences International$84.86M$0.836.748.47N/A50.90%21.25%10.56%N/AFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/AOGIOrganigram Global-$33.39M$0.0534.21N/AN/A2.86%-8.19%-5.79%N/APGNXProgenics Pharmaceuticals-$68.55M-$0.80N/AN/AN/A-180.28%-129.46%-53.23%N/ASTSASatsuma Pharmaceuticals-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/ALatest PGNX, FLXN, OGI, BDSI, and STSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q3 2025OGIOrganigram Global-$0.01-$0.03-$0.02-$0.03$68.04 million$50.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDSIBioDelivery Sciences InternationalN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/APGNXProgenics PharmaceuticalsN/AN/AN/AN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDSIBioDelivery Sciences International0.292.452.17FLXNFlexion TherapeuticsN/A4.384.05OGIOrganigram GlobalN/A2.591.42PGNXProgenics Pharmaceuticals0.992.122.12STSASatsuma PharmaceuticalsN/A7.447.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDSIBioDelivery Sciences International64.40%FLXNFlexion Therapeutics90.01%OGIOrganigram Global34.63%PGNXProgenics Pharmaceuticals70.96%STSASatsuma Pharmaceuticals93.26%Insider OwnershipCompanyInsider OwnershipBDSIBioDelivery Sciences International9.98%FLXNFlexion Therapeutics9.13%OGIOrganigram Global0.09%PGNXProgenics Pharmaceuticals4.26%STSASatsuma Pharmaceuticals31.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDSIBioDelivery Sciences International200103.23 million92.93 millionOptionableFLXNFlexion Therapeutics25750.32 million45.73 millionNo DataOGIOrganigram Global860134.05 million133.93 millionOptionablePGNXProgenics Pharmaceuticals7986.60 millionN/AOptionableSTSASatsuma Pharmaceuticals2133.15 million22.81 millionNot OptionablePGNX, FLXN, OGI, BDSI, and STSA HeadlinesRecent News About These CompaniesSatsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific MeetingJune 19, 2025 | prnewswire.comDurham-based Satsuma wins FDA approval for migraine treatmentMay 21, 2025 | ncbiotech.orgNNon-Postoperative Acute Pain Market Poised for Significant Expansion by 2034, Amid FDA Approvals and Innovative Therapeutic Pipeline | DelveInsightMay 16, 2025 | theglobeandmail.comFDA approves Atzumi for acute migraine treatment in adultsMay 6, 2025 | healio.comHFDA Okays Dihydroergotamine Nasal Spray for Acute MigraineMay 5, 2025 | medscape.comMNasal Powder for Acute Migraine Gets FDA NodMay 2, 2025 | msn.comFDA clears Satsuma’s Atzumi for migraineMay 2, 2025 | bioworld.comBSatsuma Pharmaceuticals Announces U.S. FDA Approval for AtzumiMay 1, 2025 | contractpharma.comCSatsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of MigraineApril 30, 2025 | prnewswire.comSatsuma Pharmaceuticals Inc (STSA)April 10, 2025 | uk.investing.comSatsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without AuraNovember 26, 2024 | prnewswire.comSNBL’s Subsidiary Resubmits Migraine Drug ApplicationOctober 31, 2024 | markets.businessinsider.comSatsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without AuraOctober 30, 2024 | prnewswire.comAprea Therapeutics (NASDAQ:APRE) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.comSatsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS DrugsOctober 8, 2024 | prnewswire.comSatsuma, AL Weather ConditionsAugust 21, 2024 | wunderground.comWSatsuma pulped as acute migraine drug flunks phase 3 trialAugust 9, 2024 | pharmaphorum.comPSatsuma, FL Weather ConditionsJuly 29, 2024 | wunderground.comWSatsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific MeetingJune 13, 2024 | prnewswire.comWith manufacturing-related rejection, FDA turns its nose up at Satsuma's migraine nasal sprayJanuary 18, 2024 | fiercepharma.comFNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Renaissance Hedge Fund Adds NVIDIA, Follows Buffett Into UNHBy Leo Miller | August 20, 2025Dueling Insider Moves: Heavy Buying Here, Big Selling ThereBy Leo Miller | September 2, 2025Insiders Sell These High-Quality Stocks: Why Investors Shouldn’tBy Thomas Hughes | September 8, 2025Potential Rate Cuts Could Benefit These FirmsBy Nathan Reiff | September 8, 2025PGNX, FLXN, OGI, BDSI, and STSA Company DescriptionsBioDelivery Sciences International NASDAQ:BDSIBioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.Flexion Therapeutics NASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.Organigram Global NASDAQ:OGI$1.71 +0.05 (+3.01%) Closing price 04:00 PM EasternExtended Trading$1.70 0.00 (-0.29%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Progenics Pharmaceuticals NASDAQ:PGNXProgenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.Satsuma Pharmaceuticals NASDAQ:STSASatsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
